GlassScriptPhysician profile
Charles Brooks Levin
NPI 1235138470
$3,575.63
in general payments reported to CMS, 2019-2025
31 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $181 · 2021: $598 · 2022: $380 · 2023: $627 · 2024: $707 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $634.53 | 2019-2024 | |
| Heartflow, INC. | $361.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $266.52 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $242.03 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $217.26 | 2019-2024 | Watchman Flx, Bodyguardian |
| Merck Sharp & Dohme LLC | $213.09 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $204.98 | 2019-2024 | Camzyos, Eliquis |
| Intact Vascular, INC. | $175.00 | 2019 | |
| Amgen INC. | $160.69 | 2019-2022 | |
| Abiomed | $148.55 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $144.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.45 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $104.96 | 2019-2025 | Brilinta, Wainua |
| Novo Nordisk INC | $72.09 | 2022-2025 | Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $52.77 | 2024 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.33 | 2019-2024 | Jardiance |
| Abbott Laboratories | $43.16 | 2025 | Aveir |
| Bard Peripheral Vascular, INC. | $42.19 | 2023 | Lutonix Drug Coated Balloon |
| Esperion Therapeutics, INC. | $38.12 | 2020-2022 | |
| Siemens Medical Solutions USA, INC. | $32.17 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.61 | 2024 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $25.61 | 2019 | |
| Inspire Medical Systems, INC. | $25.14 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $23.27 | 2019 | |
| Resmed Corp | $22.67 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $22.04 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.39 | 2021 | |
| Itamar Medical INC | $13.23 | 2022 | |
| Tactile Systems Technology INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.